ArticleFrontiers in endocrinology2019
The Effect of Atorvastatin (and Subsequent Metformin) on Adipose Tissue Acylation-Stimulatory-Protein Concentration and Inflammatory Biomarkers in Overweight/Obese Women With Polycystic Ovary Syndrome.
Article in Frontiers in endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Statins for women with polycystic ovary syndrome not actively trying to conceive.The Cochrane database of systematic reviews · 2023Pooled it
- Effect of atorvastatin on testosterone levels.The Cochrane database of systematic reviews · 2021Pooled it
- Beyond glycemic control: molecular mechanisms of metformin in modulating cytokine networks in polycystic ovary syndrome.Frontiers in endocrinology · 2026Review
- Pathogenesis and treatment of obesity-related polycystic ovary syndrome.Journal of ovarian research · 2025Review
- Laurolitsine ameliorates insulin resistance, ovarian dysfunction and gut microbiota dysbiosis in DHEA plus HFD-induced PCOS mice.Frontiers in endocrinology · 2025Article
- Statins for polycystic ovary syndrome in varying resource settings: a phenome-wide association study and evidence synthesis.Frontiers in pharmacology · 2025Article
- Mangiferin ameliorates polycystic ovary syndrome in rats by modulating insulin resistance, gut microbiota, and ovarian cell apoptosis.Frontiers in pharmacology · 2024Article
- Dominant-negative HNF1α mutant promotes liver steatosis and inflammation by regulating hepatic complement factor D.iScience · 2023Article
- Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics.Journal of clinical medicine · 2023Review
- Curcumin Inhibits Hyperandrogen-Induced IRE1Oxidative medicine and cellular longevity · 2022Article
- Mitochondrial Dysfunction and Chronic Inflammation in Polycystic Ovary Syndrome.International journal of molecular sciences · 2021Review
- Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS.International journal of molecular sciences · 2020Review
- A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome.Therapeutic advances in endocrinology and metabolism · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.